Perspective Therapeutics (CATX) Capital Expenditures (2010 - 2025)

Perspective Therapeutics (CATX) has 16 years of Capital Expenditures data on file, last reported at $12.7 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 13.34% year-over-year to $12.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (down 86.3% YoY), and the FY2025 full-year result was $12.7 million, down 76.57% from the prior year.
• Capital Expenditures grew to $12.7 million in Q4 2025, from $39000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $29.7 million in Q3 2024 to a low of -$4.6 million in Q2 2025.
• A 5-year average of $3.8 million and a median of $176000.0 in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures sank 243.33% in 2021 and jumped 16320.22% in 2024, its largest moves.
• Tracing CATX's Capital Expenditures over 5 years: stood at -$86000.0 in 2021, then soared by 275.58% to $151000.0 in 2022, then sank by 41.06% to $89000.0 in 2023, then jumped by 16320.22% to $14.6 million in 2024, then retreated by 13.34% to $12.7 million in 2025.
• Business Quant data shows CATX's Capital Expenditures at $12.7 million in Q4 2025, $39000.0 in Q3 2025, and -$4.6 million in Q2 2025.